FBRX
FBRX
NASDAQ · Biotechnology

Forte Biosciences Inc

$26.37
+0.65 (+2.53%)
As of Mar 25, 3:11 PM ET ·
Financial Highlights (FY 2026)
Revenue
320.9K
Net Income
-152,009,038
Gross Margin
Profit Margin
-158,800.0%
Rev Growth
-7.2%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 51.3% 51.3%
Operating Margin -150,175.0% -135,157.9% -27.6% -27.7%
Profit Margin -158,800.0% -150,860.0% -29.2% -24.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 320.9K 345.6K 44.14M 46.50M
Gross Profit 22.64M 23.85M
Operating Income -481,839,491 -467,150,212 -12,199,696 -12,900,376
Net Income -152,009,038 -147,374,915 -12,888,213 -11,210,008
Gross Margin 51.3% 51.3%
Operating Margin -150,175.0% -135,157.9% -27.6% -27.7%
Profit Margin -158,800.0% -150,860.0% -29.2% -24.1%
Rev Growth -7.2% -7.2% -3.2% -9.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 74.91M 81.84M
Total Equity 274.64M 271.93M
D/E Ratio 0.27 0.30
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -151,839,100 -155,388,500 -17,594,581 -16,493,957
Free Cash Flow -11,802,396 -11,084,789